We provide clinical information and insights to help you serve plan members, manage costs and avoid surprises. Find essential safety recalls, new drug announcements and other clinical news here.
Contact your Account Manager or Clinical Account Executive for additional details or if you have specific questions.
Looking for more CastiaRx news?
Visit The Edge
This monthly update highlights recently approved brand and generic drugs as well as new to market therapies. Read More
The FDA is requesting the immediate withdrawal of all prescription and over-the-counter (OTC) ranitidine drugs from the market due to increased suspicion of NDMA in the products. Read More
An increasing number of diabetes medications have been proven to reduce the risk of having a heart attack or stroke. Read More
The FDA approved Descovy® for use as a pre-exposure prophylaxis (PrEP) medication to reduce the risk of HIV infection.
Reyvow© is the first and only drug in a new class of acute treatment for migraine approved by the FDA.
The FDA approved a new acne topical treatment, Aklief®, the first new retinoid molecule to be approved in over 20 years.
The FDA approved a new breakthrough therapy, Trikafta™, which has the potential to benefit up to 90% of cystic fibrosis patients.
VylessiTM is the first medication on the market that offers an as-needed solution for hypoactive sexual desire disorder (HSDD).
The big switch from brand to generic is a seamless process. Learn how the choices made during plan setup guide the transition.
The FDA approved nine generic versions of pregabalin that are now available at a significantly lower price than Lyrica.
Novitium Pharma received approval from the FDA for the first generic sildenafil suspension to treat pulmonary arterial hypertension.
Teva launched its generic version of the overactive bladder drug and a month later additional manufacturers followed suit.
The lower-priced generic, Insulin Lispro, is commercially available as an authorized generic of Humalog.
The FDA is requesting the immediate withdrawal of all prescription and over-the-counter (OTC) ranitidine drugs from the market due to increased suspicion of NDMA in the products.
Two lots of the anti-epileptic drug are being recalled due to potential for inaccurate dosing.
The FDA has requested the voluntary withdrawal of Belviq and Belviq XR from the market due to increased occurrence of cancer.
One lot of the epilepsy and bipolar disorder medication is being voluntarily recalled due to cross-contamination with another substance.
One lot of the anxiety management medication is being recalled due to the potential presence of a foreign substance.
This monthly update highlights recently approved brand and generic drugs as well as new to market therapies.
An increasing number of diabetes medications have been proven to reduce the risk of having a heart attack or stroke.
This monthly update highlights recently approved brand and generic drugs as well as new to market therapies.
This quarterly drug development pipeline highlights new and emerging therapies, including both traditional and specialty medications.
This quarterly drug pipeline includes first-time generic drugs seeking FDA approval in the next two years.